MedTrace Logo

Safety and Efficiency of γδ T Cell Against Lung Cancer

NCT03183232 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-07-13

No results posted yet for this study

Summary

In this study, effects of γδT cells on human Lung Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated

Conditions

Interventions

PROCEDURE

Cryosurgery or IRE surgery

Cryosurgery or IRE surgery will be used in local tumor

BIOLOGICAL

γδ T cell

γδ T cells will be used against Lung Cancer

OTHER

γδ T cells/ A Cryosurgery or IRE

Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer

Sponsors & Collaborators

  • Jinan University Guangzhou

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, PhD · Biological treatment center in Fuda cancer hospital Guangzhou, Guangdong, China, 510000

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2018-06-15
Completion
2019-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03183232 on ClinicalTrials.gov